HONG KONG – Recovering from an acquisition bid in June that ultimately sent its shares down by about 20 percent, Chinese drugmaker Luye Pharma Group Ltd. is back on the deal trail, this time with plans to acquire Singapore-based molecular diagnostics firm Vela Diagnostics Pte Ltd.